Individual patients, individual needs: a nurse practitioner shares her experiences with COPD treatment options.

Updated | Posted

Chronic obstructive pulmonary disease (COPD) affects a diverse patient population, each with their own set of preferences and needs.1 Nurse Practitioner Dana Hickman, MSN, discusses her experiences prescribing a treatment option for COPD, and speaks to the importance of individualizing treatment.

LONHALA® MAGNAIR® (glycopyrrolate) is an anticholinergic indicated for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

LONHALA MAGNAIR is contraindicated in patients with a hypersensitivity to glycopyrrolate or to any of the ingredients.

Please see Important Safety Information featured in the video above and full Prescribing Information and Patient Information for LONHALA MAGNAIR at

GOLD does not endorse any specific treatments.

GOLD = Global Initiative for Chronic Obstructive Lung Disease.


1. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 
    Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2020:1-125.

This topic is now closed to further replies.